Substance / Medication

Epcoritamab

Overview

Active Ingredient
epcoritamab
RxNorm CUI
2637392
Labeler: Genmab US, Inc.Updated: 2025-11-25T00:00:00.000ZFull label on DailyMed

Boxed Warning

FDA Black Box Warning

Dosage and Administration (2.1 2.2 2.6) Warnings and Precautions (5.1) [see,,and] Cytokine release syndrome (CRS), including serious or fatal reactions, can occur in patients receiving EPKINLY. Initiate treatment with the EPKINLY step-up dosage schedule to reduce the incidence and severity of CRS. W

Contraindications

When this intervention should not be used

None.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Epcoritamab monotherapy for Richter transformation (EPCORE CLL-1): findings from a single-arm, multicentre, open-label, phase 1b/2 trial.
Kater Arnon P, Janssens Ann, Eradat Herbert et al. · Lancet Haematol · 2026
PMID: 41380698Observational
Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab.
Brooks Taylor R, Zabor Emily C, Bedelu Yohanna B et al. · Blood · 2025
PMID: 40663785Observational
Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial.
Thieblemont Catherine, Karimi Yasmin H, Ghesquieres Herve et al. · Leukemia · 2024
PMID: 39322711ObservationalFull text (PMC)
Epcoritamab as bridging therapy to successful second allogeneic HSCT in relapsed DLBCL after UCBT and CAR T cell therapy.
Chikagawa Yui, Higashi Daiki, Sakai Satoomi et al. · Int J Hematol · 2026
PMID: 41143946Case Report
The effective and safe administration of Epcoritamab in relapsed CD19-CD5+ DLBCL following CAR-T therapy.
Shimakawa Takashi, Kawano Noriaki, Semba Yuichiro et al. · Blood Cell Ther · 2025
PMID: 40927278Case ReportFull text (PMC)
Epcoritamab-Induced fatal pleural effusion in diffuse large B-Cell lymphoma: a case report and literature review.
Takahata Atsushi, Shimada Tomohito, Bando Kana et al. · Ann Hematol · 2025
PMID: 39825138Case ReportFull text (PMC)
Utility of CSF IL-6 monitoring in managing ICANS associated with Epcoritamab treatment: a case report and literature review.
Takahata Atsushi, Akita Kaori, Shimada Tomohito et al. · J Clin Exp Hematop · 2025
PMID: 40159285Case ReportFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Epcoritamab (substance)
SNOMED CT
1363209009
UMLS CUI
C5418281
RxNorm CUI
2637392
Labeler
Genmab US, Inc.

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.